drugset / Trial / NCT05010629
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
Timeline
- Start
- 2021-09-14
- Primary completion
- 2025-02-14
- Completion
- 2027-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elraglusib | Small molecule | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |